These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11641975)

  • 21. A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation.
    Karademir K; Baykal K; Sen B; Senkul T; Iseri C; Erden D
    Scand J Urol Nephrol; 2005; 39(3):230-3. PubMed ID: 16118096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of oxybutynin treatment on cognition in children with diurnal incontinence.
    Sommer BR; O'Hara R; Askari N; Kraemer HC; Kennedy WA
    J Urol; 2005 Jun; 173(6):2125-7. PubMed ID: 15879864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Achieving bladder control. Treatment in the primary care setting.
    Maloney CM; Cafiero M
    Adv Nurse Pract; 2002 May; 10(5):73-8. PubMed ID: 12420535
    [No Abstract]   [Full Text] [Related]  

  • 24. Effectiveness of iontophoresis with alternating current (AC) in the treatment of patients with palmoplantar hyperhidrosis.
    Shimizu H; Tamada Y; Shimizu J; Ohshima Y; Matsumoto Y; Sugenoya J
    J Dermatol; 2003 Jun; 30(6):444-9. PubMed ID: 12810991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity.
    Bach P; Wormland RT; Möhring C; Goepel M
    Neurourol Urodyn; 2009; 28(3):209-13. PubMed ID: 19205067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl oxybutynin.
    Di Stasi SM; Giannantoni A; Navarra P; Capelli G; Storti L; Porena M; Stephen RL
    J Urol; 2001 Dec; 166(6):2232-6. PubMed ID: 11696741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed?
    Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M
    Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Event driven electrical stimulation of the dorsal penile/clitoral nerve for management of neurogenic detrusor overactivity in multiple sclerosis.
    Fjorback MV; Rijkhoff N; Petersen T; Nohr M; Sinkjaer T
    Neurourol Urodyn; 2006; 25(4):349-55. PubMed ID: 16673380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of Systemic Therapies to Manage Focal Hyperhidrosis.
    Glaser DA; Glaser K
    Mo Med; 2015; 112(4):287-91. PubMed ID: 26455059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity.
    Salvatore S; Khullar V; Cardozo L; Milani R; Athanasiou S; Kelleher C
    Eur J Obstet Gynecol Reprod Biol; 2005 Apr; 119(2):237-41. PubMed ID: 15808387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Less disability in daily activities].
    Krankenpfl J; 2005; 43(7-10):191. PubMed ID: 16515263
    [No Abstract]   [Full Text] [Related]  

  • 32. Chronic pudendal nerve neuromodulation in women with idiopathic refractory detrusor overactivity incontinence: results of a pilot study with a novel minimally invasive implantable mini-stimulator.
    Groen J; Amiel C; Bosch JL
    Neurourol Urodyn; 2005; 24(3):226-30. PubMed ID: 15825153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial.
    Silva C; Silva J; Ribeiro MJ; Avelino A; Cruz F
    Eur Urol; 2005 Oct; 48(4):650-5. PubMed ID: 15961217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravesical treatment of bladder dysfunction.
    Zimmern P
    J Urol; 2001 Dec; 166(6):2241. PubMed ID: 11696743
    [No Abstract]   [Full Text] [Related]  

  • 35. Refractory monosymptomatic nocturnal enuresis: a combined stepwise approach in childhood and follow-up into adolescence, with attention to the clinical value of normalizing bladder capacity.
    Vermandel A; de Wachter S; Wyndaele JJ
    BJU Int; 2005 Sep; 96(4):629-33. PubMed ID: 16104923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxybutynin therapy for generalized hyperhidrosis.
    Tupker RA; Harmsze AM; Deneer VH
    Arch Dermatol; 2006 Aug; 142(8):1065-6. PubMed ID: 16924061
    [No Abstract]   [Full Text] [Related]  

  • 37. Enuresis.
    Cossio SE
    South Med J; 2002 Feb; 95(2):183-7. PubMed ID: 11846242
    [No Abstract]   [Full Text] [Related]  

  • 38. This month in investigative urology: new insights into the clinical value of oxybutynin.
    Chai TC
    J Urol; 1998 Sep; 160(3 Pt 1):644. PubMed ID: 9720514
    [No Abstract]   [Full Text] [Related]  

  • 39. Transvaginal electrical stimulation in the treatment of urinary incontinence.
    Wein AJ
    J Urol; 2005 Sep; 174(3):1007. PubMed ID: 16094024
    [No Abstract]   [Full Text] [Related]  

  • 40. [Diagnosis and treatment of urinary bladder dysfunctions in patients with nephrotuberculosis].
    Zuban' ON; Iagafarova RK; Vinogradova TI
    Urologiia; 2006; (5):37-40, 45. PubMed ID: 17444151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.